References
- Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer 1988;62:2152-2165 https://doi.org/10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T
- Pedersen CL, Romner B. Current treatment of low grade astrocytoma: a review. Clin Neurol Neurosurg 2013;115:1-8 https://doi.org/10.1016/j.clineuro.2012.07.002
- Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008;116:597-602 https://doi.org/10.1007/s00401-008-0455-2
- Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009;15:6002-6007 https://doi.org/10.1158/1078-0432.CCR-09-0715
- Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-773 https://doi.org/10.1056/NEJMoa0808710
- Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010;120:707-718 https://doi.org/10.1007/s00401-010-0781-z
- Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-1812 https://doi.org/10.1126/science.1164382
- Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150-4154 https://doi.org/10.1200/JCO.2009.21.9832
- Levner I, Drabycz S, Roldan G, De Robles P, Cairncross JG, Mitchell R. Predicting MGMT methylation status of glioblastomas from MRI texture. Med Image Comput Comput Assist Interv 2009;12:522-530
- Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006;129:1884-1891 https://doi.org/10.1093/brain/awl108
- Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker FG 2nd. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 2005;11:8600-8605 https://doi.org/10.1158/1078-0432.CCR-05-0713
- Mut M, Turba UC, Botella AC, Baskurt E, Lopes MB, Shaffrey ME. Neuroimaging characteristics in subgroup of GBMs with p53 overexpression. J Neuroimaging 2007;17:168-174 https://doi.org/10.1111/j.1552-6569.2007.00112.x
- DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-845 https://doi.org/10.2307/2531595
- Lee S, Choi SH, Ryoo I, et al. Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusionweighted imaging and dynamic-susceptibility contrast perfusion imaging. J Neurooncol 2015;121:141-150 https://doi.org/10.1007/s11060-014-1614-z
- Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res 2013;19:764-772 https://doi.org/10.1158/1078-0432.CCR-12-3002
- Paganetti PA, Caroni P, Schwab ME. Glioblastoma infiltration into central nervous system tissue in vitro: involvement of a metalloprotease. J Cell Biol 1988;107:2281-2291 https://doi.org/10.1083/jcb.107.6.2281
- Andronesi OC, Rapalino O, Gerstner E, et al. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest 2013;123:3659-3663 https://doi.org/10.1172/JCI67229
- Pope WB, Prins RM, Albert Thomas M, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol 2012;107:197-205 https://doi.org/10.1007/s11060-011-0737-8
- Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDHmutated patients with gliomas. Nat Med 2012;18:624-629 https://doi.org/10.1038/nm.2682
- SongTao Q, Lei Y, Si G, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 2012;103:269-273 https://doi.org/10.1111/j.1349-7006.2011.02134.x
- Tran AN, Lai A, Li S, et al. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro Oncol 2014;16:414-420 https://doi.org/10.1093/neuonc/not198
- Carrillo JA, Lai A, Nghiemphu PL, et al. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 2012;33:1349-1355 https://doi.org/10.3174/ajnr.A2950
- Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012;3:709-722